<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lenz Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/lenz-therapeutics-inc</link>
<description>Latest news and press releases for Lenz Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lenz-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835909678dffbe2df10219c.webp</url>
<title>Lenz Therapeutics Inc</title>
<link>https://6ix.com/company/lenz-therapeutics-inc</link>
</image>
<item>
<title>LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-the-medicines-and-healthcare-products-regulatory-agency-for-vizzr-for-the-treatment-of-presbyopia-in-the-united-kingdom</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-the-medicines-and-healthcare-products-regulatory-agency-for-vizzr-for-the-treatment-of-presbyopia-in-the-united-kingdom</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and onl</description>
</item>
<item>
<title>LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in</description>
</item>
<item>
<title>LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights-on-march-24-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights-on-march-24-2026</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the</description>
</item>
<item>
<title>LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-european-medicines-agency-for-vizzr-for-the-treatment-of-presbyopia</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-submission-of-marketing-authorization-application-to-european-medicines-agency-for-vizzr-for-the-treatment-of-presbyopia</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ’s strategy to expand global access to VIZZ Submission of MAA in</description>
</item>
<item>
<title>LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-sarah-jessica-parker-133000248</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-sarah-jessica-parker-133000248</guid>
<pubDate>Wed, 14 Jan 2026 13:30:00 GMT</pubDate>
<description>Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The “Make it VIZZable” campaign features SJP enjoying the everyday convenience of clear near vision provided by using the VIZZ eye drops. VIZZ is available nationwide by prescription through eye doctors; visit VIZZ.com to learn more and to find a local provider offering a free sample SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, I</description>
</item>
<item>
<title>LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-and-sarah-jessica-parker-announce-launch-make-it-vizzable-vizz-0</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-and-sarah-jessica-parker-announce-launch-make-it-vizzable-vizz-0</guid>
<pubDate>Wed, 14 Jan 2026 05:00:00 GMT</pubDate>
<description>Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hoursThe "Make</description>
</item>
<item>
<title>LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-reports-fourth-quarter-220800088</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-reports-fourth-quarter-220800088</guid>
<pubDate>Wed, 07 Jan 2026 22:08:00 GMT</pubDate>
<description>Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025 Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025 SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company foc</description>
</item>
<item>
<title>LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-and-lunatus-announce-exclusive-commercialization-partnership-vizztm</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-and-lunatus-announce-exclusive-commercialization-partnership-vizztm</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZ SAN DIEGO and DUBAI, United Arab Emirates,</description>
</item>
<item>
<title>LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-mfds-submission-new-drug-application-lnz100-vizztm-south</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-mfds-submission-new-drug-application-lnz100-vizztm-south</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ SAN DIEGO and TAIPEI, Taiwan, Dec. 01,</description>
</item>
<item>
<title>LENZ Therapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-present-upcoming-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-present-upcoming-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the</description>
</item>
<item>
<title>LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-reports-third-quarter-2025-financial-results-and-recent-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-reports-third-quarter-2025-financial-results-and-recent-corporate</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with</description>
</item>
<item>
<title>LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-report-third-quarter-2025-financial-results-and-recent-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-report-third-quarter-2025-financial-results-and-recent-corporate</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the</description>
</item>
<item>
<title>Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/artelo-biosciences-names-veteran-life-sciences-executive-mark-spring-cpa-as-chief-financial-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/artelo-biosciences-names-veteran-life-sciences-executive-mark-spring-cpa-as-chief-financial-officer-1</guid>
<pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointmen</description>
</item>
<item>
<title>LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-commercial-product-availability-vizztm-united-states-0</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-commercial-product-availability-vizztm-united-states-0</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad</description>
</item>
<item>
<title>LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-commercial-product-availability-vizztm-united-states-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-commercial-product-availability-vizztm-united-states-2025</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad</description>
</item>
<item>
<title>LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-present-upcoming-investor-and-medical-conferences-2025-08-25</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-present-upcoming-investor-and-medical-conferences-2025-08-25</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the</description>
</item>
<item>
<title>LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-us-fda-approval-vizztm-treatment-presbyopia-2025-07-31</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-us-fda-approval-vizztm-treatment-presbyopia-2025-07-31</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128</description>
</item>
<item>
<title>LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-reports-second-quarter-2025-financial-results-and-recent-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-reports-second-quarter-2025-financial-results-and-recent-corporate</guid>
<pubDate>Wed, 30 Jul 2025 04:00:00 GMT</pubDate>
<description>New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and</description>
</item>
<item>
<title>LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-nmpa-submission-new-drug-application-lnz100-china</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-announces-nmpa-submission-new-drug-application-lnz100-china</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and</description>
</item>
<item>
<title>LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada</title>
<link>https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and</link>
<guid isPermaLink="true">https://6ix.com/company/lenz-therapeutics-inc/news/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and</guid>
<pubDate>Mon, 07 Jul 2025 04:00:00 GMT</pubDate>
<description>Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales SAN DIEGO and</description>
</item>
</channel>
</rss>